HLB Therapeutics Co.,Ltd.
KOSDAQ 115450.KQ
HLB Therapeutics Co.,Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -375.90
-
HLB Therapeutics Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is -128.06 on January 17, 2024, which is 65.93% above the current Price to Earnings Ratio (P/E).
-
HLB Therapeutics Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is -551.26 on April 08, 2024, which is -46.65% below the current Price to Earnings Ratio (P/E).
-
HLB Therapeutics Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -310.70.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Mr. Doug Jang |
| IPO Date | March 26, 2010 |
| Location | |
| Headquarters | Parkview Office Tower |
| Employees | 98 |
| Sector | Health Care |
| Industries | |
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email